Agios Pharmaceuticals reports positive data on three of its experimental compounds at the EHA meeting in Vienna, and yet shares are tumbling. Find out what data point has investors spooked and whether you should really be worried.
Agios Pharmaceuticals reports positive data on three of its experimental compounds at the EHA meeting in Vienna, and yet shares are tumbling. Find out what data point has investors spooked and whether you should really be worried.